An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Ovarian cancer is the most lethal gynecological cancer and the 5th leading cause of cancer death in women. Platinum chemotherapy has been widely adopted as a standard treatment for advanced ovarian cancer, the response rates in patients with relapsed/refractory ovarian cancer is unacceptably low. PD‐1 blockade has been developed to a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance T‐cell‐mediated anticancer immune responses. Manganese has been confirmed to activate antigen‐presenting cells and function as mucosal immunoadjuvants in pre‐clinical studies. This two‐arm, phase I/II study is designed to assess the safety and efficacy of combined therapy of anti‐PD‐1 antibody and chemotherapy with or without Manganese priming.